425: Strive CEO Reposts Semler Scientific Merger Update

Strive's CEO reposted an update on X.com regarding the proposed business combination with Semler Scientific, highlighting the ongoing process and associated risks.

Summary

• A communication was reposted on X.com by Matthew Cole, Chief Executive Officer of Strive, Inc., on October 1, 2025.
• The communication pertains to Strive's proposed business combination with Semler Scientific, Inc.
• It includes a cautionary statement regarding forward-looking statements, emphasizing inherent risks and uncertainties.
• Strive intends to file a Registration Statement on Form S-4 with the SEC, which will include an Information Statement/Proxy Statement/Prospectus.
• Investors and stockholders of Semler Scientific are urged to read the forthcoming SEC filings for important information about the proposed transaction.
• Strive, Semler Scientific, and certain directors, executive officers, and employees may be deemed participants in the solicitation of proxies.
• The communication explicitly states it is not an offer to sell or solicit securities or votes.

Sentiment

Score: 4

Explanation: The filing is primarily a cautionary statement detailing numerous risks associated with a proposed business combination, leading to a cautious sentiment. While it indicates progress on the merger, the emphasis is heavily on potential negative outcomes and uncertainties.

Positives

• The proposed business combination between Strive and Semler Scientific is actively progressing.
• Strive plans to file a comprehensive Registration Statement on Form S-4, providing detailed information to investors and stockholders.

Negatives

• The proposed transaction may not close as expected or at all if conditions are not met.
• Anticipated benefits, including cost savings and strategic gains, may not be realized.
• Integration of the two companies could be more difficult, time-consuming, or costly than expected.
• The transaction may incur higher expenses or take longer to complete than anticipated.
• Management's attention may be diverted from ongoing business operations and opportunities.
• Strive's issuance of additional Class A common stock in connection with the transaction will cause dilution.
• There is a risk of adverse reactions from customers or changes to business or employee relationships.
• Changes in Strive's or Semler Scientific's share price may occur before closing.

Risks

• The merger agreement could be terminated by either Strive or Semler Scientific.
• Conditions to closing the proposed transaction may not be received or satisfied on a timely basis or at all.
• Legal proceedings may be instituted against Strive, Semler Scientific, or the combined company.
• Anticipated benefits, including cost savings and strategic gains, may not be realized, partly due to risks associated with Bitcoin treasury strategies and other digital assets.
• General economic and market conditions, interest and exchange rates, monetary policy, and regulatory changes could impact the transaction.
• Integration of the two companies may be more difficult, time-consuming, or costly than expected.
• The proposed transaction may be more expensive or take longer to complete than anticipated.
• Management's attention may be diverted from ongoing business operations.
• Dilution caused by Strive's issuance of additional shares of its Class A common stock.
• Potential adverse reactions from customers or changes to business or employee relationships.
• Changes in Strive's or Semler Scientific's share price before closing.
• Other unknown or unpredictable factors could harm the results of Strive, Semler Scientific, or the combined company.

Future Outlook

Expectations for the proposed transaction, including strategic and financial benefits, impact on the combined company's future financial performance, timing of closing, and successful integration of businesses, are subject to significant risks and uncertainties. Actual results may differ materially from these forward-looking statements.

Management Comments

• Matthew Cole, Chief Executive Officer of Strive, Inc., reposted the communication on X.com.
• Strive and Semler Scientific believe their expectations with respect to forward-looking statements are based upon reasonable assumptions, but there can be no assurance that actual results will not differ materially.

Industry Context

This communication is a standard regulatory disclosure for a proposed business combination, emphasizing the inherent risks. The mention of 'Bitcoin treasury strategies and risks associated with Bitcoin and other digital assets' suggests a potential strategic focus for the combined entity, aligning with broader corporate interest in digital assets.

Legal Proceedings

• The possibility that legal proceedings may be instituted against Strive or Semler Scientific or the combined company is identified as a risk.

Related Party Transactions

• Information about Semler Scientific's transactions with related persons is set forth in its definitive proxy statement for its 2025 Annual Meeting of Stockholders.

Stakeholder Impact

• Shareholders: Potential dilution from Strive's issuance of additional Class A common stock, changes in share price, and the need to approve the proposed transaction.
• Customers: Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction.
• Employees: Potential changes to employee relationships due to the proposed transaction.

Next Steps

• Strive intends to file a Registration Statement on Form S-4 with the SEC.
• The Registration Statement will include an Information Statement/Proxy Statement/Prospectus.
• A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval of the proposed transaction.
• Investors and stockholders are urged to read the Registration Statement and Information Statement/Proxy Statement/Prospectus when they become available.

Key Dates

Recommendation

This filing is a standard Form 425 communication related to a proposed business combination between Strive and Semler Scientific, primarily serving as a cautionary statement regarding forward-looking information and outlining various risks associated with the merger. It does not present new financial results or strategic shifts that would warrant an immediate change in investment posture. Investors should hold their positions and await the full Registration Statement on Form S-4 and Information Statement/Proxy Statement/Prospectus for a comprehensive understanding of the transaction's terms, financial implications, and detailed risk assessment before making further investment decisions.

Keywords

Strive Inc., Semler Scientific Inc., Merger, Acquisition, Business Combination, SEC Filing, Form 425, Forward-Looking Statements, Risk Factors, Bitcoin Treasury Strategy, Corporate Governance